• Publications
  • Influence
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase belonging to the HER family of receptor tyrosine kinases. Receptor activation upon ligand binding leads to down streamExpand
  • 166
  • 11
AXL mediates resistance to cetuximab therapy.
The EGFR antibody cetuximab is used to treat numerous cancers, but intrinsic and acquired resistance to this agent is a common clinical outcome. In this study, we show that overexpression of theExpand
  • 122
  • 11
  • PDF
Nuclear EGFR as a molecular target in cancer.
The epidermal growth factor receptor (EGFR) has been one of the most targeted receptors in the field of oncology. While anti-EGFR inhibitors have demonstrated clinical success in specific cancers,Expand
  • 139
  • 9
The nuclear epidermal growth factor receptor signaling network and its role in cancer.
The epidermal growth factor receptor (EGFR) is a member of the EGFR family of receptor tyrosine kinases (RTKs). EGFR activation via ligand binding results in signaling through various pathwaysExpand
  • 181
  • 6
Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a subclass of breast cancers (i.e., estrogen receptor–negative, progesterone receptor–negative, and HER2-negative) that have poor prognosis and very fewExpand
  • 40
  • 5
Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Purpose: Human papillomavirus (HPV) 16 plays an etiologic role in a growing subset of head and neck squamous cell carcinomas (HNSCC), where viral expression of the E6 and E7 oncoproteins is necessaryExpand
  • 23
  • 4
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
Purpose: Head and neck squamous cell carcinoma (HNSCC) represents the eighth most common malignancy worldwide. Standard-of-care treatments for patients with HNSCC include surgery, radiation, andExpand
  • 64
  • 3
  • PDF
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.
INTRODUCTION Nuclear EGFR (nEGFR) has been identified in various human tumor tissues, including cancers of the breast, ovary, oropharynx, and esophagus, and has predicted poor patient outcomes. WeExpand
  • 52
  • 3
Yes and Lyn play a role in nuclear translocation of the Epidermal Growth Factor Receptor
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in human cancers. Cetuximab is an anti-EGFR antibody that has been approved for use in oncology. Previously weExpand
  • 59
  • 2
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for headExpand
  • 55
  • 2